Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

SURMOUNT-5

Novo Nordisk · Phase 3 · Completed · Enrollment 751

NCT05822830

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

≥5%
87.766.7
≥10%
71.745
≥15%
5531.1
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
15 mg or MTD - Tirzepatiden/r87.7%71.7%55%
2.4 mg or MTD - Semaglutiden/r66.7%45%31.1%

Not shown

Every selected arm is drawn.